154 related articles for article (PubMed ID: 1974826)
41. Further characterization of murine bone marrow-derived natural suppressor cells. Potential relationships between NS and NK/LAK activities.
Saffran DC; Singhal SK
Cell Immunol; 1990 Jun; 128(1):301-13. PubMed ID: 2140533
[TBL] [Abstract][Full Text] [Related]
42. Gelatin sponge model of effector recruitment: tumoricidal activity of adherent and non-adherent lymphokine-activated killer cells after culture in interleukin-2.
Akporiaye ET; Barbieri CA; Stewart CC; Bender JG
J Leukoc Biol; 1991 Feb; 49(2):189-96. PubMed ID: 1991999
[TBL] [Abstract][Full Text] [Related]
43. Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.
Hornung RL; Back TC; Zaharko DS; Urba WJ; Longo DL; Wiltrout RH
J Immunol; 1988 Nov; 141(10):3671-9. PubMed ID: 2460546
[TBL] [Abstract][Full Text] [Related]
44. Suppression of hepatic lymphokine-activated killer cell induction by murine Kupffer cells and hepatocytes.
Tzung SP; Gaines KC; Lance P; Ehrke MJ; Cohen SA
Hepatology; 1990 Oct; 12(4 Pt 1):644-52. PubMed ID: 2210667
[TBL] [Abstract][Full Text] [Related]
45. NK cells use NKG2D to recognize a mouse renal cancer (Renca), yet require intercellular adhesion molecule-1 expression on the tumor cells for optimal perforin-dependent effector function.
Abdool K; Cretney E; Brooks AD; Kelly JM; Swann J; Shanker A; Bere EW; Yokoyama WM; Ortaldo JR; Smyth MJ; Sayers TJ
J Immunol; 2006 Aug; 177(4):2575-83. PubMed ID: 16888019
[TBL] [Abstract][Full Text] [Related]
46. Stimulation of natural killer cell numbers but not function in leukemic infant mice: a system primed in infancy allows survival in adulthood.
Dussault I; Miller SC
Nat Immun; 1993; 12(2):66-78. PubMed ID: 8318817
[TBL] [Abstract][Full Text] [Related]
47. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.
Wysocki PJ; Kazimierczak U; Suchorska W; Kotlarski M; Malicki J; Mackiewicz A
Cancer Gene Ther; 2010 Jul; 17(7):465-75. PubMed ID: 20168352
[TBL] [Abstract][Full Text] [Related]
48. Natural suppressor (NS) cells found in the spleen of neonatal mice and adult mice given total lymphoid irradiation (TLI) express the null surface phenotype.
Oseroff A; Okada S; Strober S
J Immunol; 1984 Jan; 132(1):101-10. PubMed ID: 6228575
[TBL] [Abstract][Full Text] [Related]
49. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
[TBL] [Abstract][Full Text] [Related]
50. Generation and characterization of purified adherent lymphokine-activated killer cells in mice.
Gunji Y; Vujanovic NL; Hiserodt JC; Herberman RB; Gorelik E
J Immunol; 1989 Mar; 142(5):1748-54. PubMed ID: 2783950
[TBL] [Abstract][Full Text] [Related]
51. Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells.
Zhai YF; Esselman WJ; Oakley CS; Chang CC; Welsch CW
Cancer Immunol Immunother; 1992; 35(4):237-45. PubMed ID: 1511458
[TBL] [Abstract][Full Text] [Related]
52. TGF-beta mediates natural suppressor activity of IL-2-activated lymphocytes.
Yamamoto H; Hirayama M; Genyea C; Kaplan J
J Immunol; 1994 Apr; 152(8):3842-7. PubMed ID: 8144953
[TBL] [Abstract][Full Text] [Related]
53. Down-regulation of cytotoxic T lymphocyte development by a minor stimulating locus-induced suppressor cascade that involves Lyt-1+ suppressor T cells, IA- macrophages, and their factors.
Chow KP; Battisto JR
J Immunol; 1988 Feb; 140(4):1005-13. PubMed ID: 2963857
[TBL] [Abstract][Full Text] [Related]
54. Trafficking of 'immune' CD4(+)/CD8(+)T-lymphocytes into the RENCA tumour microcirculation in vivo in mice.
Ali SA; Rees RC; Anderson DQ; Reed MW; Goepel JR; Brown NJ
Br J Cancer; 2000 Oct; 83(8):1061-8. PubMed ID: 10993655
[TBL] [Abstract][Full Text] [Related]
55. Rejection of mouse renal cell carcinoma elicited by local secretion of interleukin-2.
Hara I; Hotta H; Sato N; Eto H; Arakawa S; Kamidono S
Jpn J Cancer Res; 1996 Jul; 87(7):724-9. PubMed ID: 8698622
[TBL] [Abstract][Full Text] [Related]
56. Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages.
Fan K; Zhou M; Pathak MK; Lindner DJ; Altuntas CZ; Tuohy VK; Borden EC; Yi T
J Immunol; 2005 Nov; 175(10):7003-8. PubMed ID: 16272361
[TBL] [Abstract][Full Text] [Related]
57. NK cells are the crucial antitumor mediators when STAT3-mediated immunosuppression is blocked in hepatocellular carcinoma.
Sui Q; Zhang J; Sun X; Zhang C; Han Q; Tian Z
J Immunol; 2014 Aug; 193(4):2016-23. PubMed ID: 25015826
[TBL] [Abstract][Full Text] [Related]
58. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
59. Indomethacin up-regulates the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2.
Eisenthal A
Cancer Immunol Immunother; 1990; 31(6):342-8. PubMed ID: 2386979
[TBL] [Abstract][Full Text] [Related]
60. The influence of tumor immunity suppressors on the effector stage of human and animal lymphokine-activated killer cells.
Abronina IF; Indrova M; Bubenic J; Figurin KM; Malakhova NV; Bykovskaya SN
Biomed Pharmacother; 1993; 47(9):371-7. PubMed ID: 8068858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
